Ocular Therapeutix, Inc. develops therapies for retinal diseases, focusing on reducing the treatment burden for patients. Its lead investigational product, AXPAXLI™ (OTX-TKI), is an axitinib hydrogel administered by intravitreal injection and is in Phase 3 clinical trials for wet age-related macular degeneration (AMD). The company aims to improve long-term vision preservation for patients affected by retinal conditions such as diabetic retinopathy and retinal vein occlusion.
